ARCALYST (rilonacept)
Recurrent Pericarditis
Key Facts
About Kiniksa Pharmaceuticals
Founded in 2015 and publicly traded on NASDAQ, Kiniksa Pharmaceuticals is dedicated to advancing transformative therapies, with a core focus on cardiovascular diseases. Its key achievement is the 2021 FDA approval and commercial launch of ARCALYST for recurrent pericarditis, providing a critical treatment for a serious inflammatory heart condition. The company's strategy involves leveraging validated immune-modulating pathways, pursuing multiple indications for its assets, and forming strategic collaborations to expand its global reach and pipeline potential.
View full company profileAbout Kiniksa Pharmaceuticals
Founded in 2015 and publicly traded on NASDAQ, Kiniksa Pharmaceuticals is dedicated to advancing transformative therapies, with a core focus on cardiovascular diseases. Its key achievement is the 2021 FDA approval and commercial launch of ARCALYST for recurrent pericarditis, providing a critical treatment for a serious inflammatory heart condition. The company's strategy involves leveraging validated immune-modulating pathways, pursuing multiple indications for its assets, and forming strategic collaborations to expand its global reach and pipeline potential.
View full company profileAbout Kiniksa Pharmaceuticals
Founded in 2015 and publicly traded on NASDAQ, Kiniksa Pharmaceuticals is dedicated to advancing transformative therapies, with a core focus on cardiovascular diseases. Its key achievement is the 2021 FDA approval and commercial launch of ARCALYST for recurrent pericarditis, providing a critical treatment for a serious inflammatory heart condition. The company's strategy involves leveraging validated immune-modulating pathways, pursuing multiple indications for its assets, and forming strategic collaborations to expand its global reach and pipeline potential.
View full company profileTherapeutic Areas
Other Recurrent Pericarditis Drugs
| Drug | Company | Phase |
|---|---|---|
| KPL-387 | Kiniksa Pharmaceuticals | Phase 2/3 |
| VTX2735 | Ventyx Biosciences | Phase 2 |